BRCA1 and carcinoma: Importantly, ROSI cotreatment increased PPARγ expression in mammary-derived lymphomas and carcinomas from PPARγ-WT and PPARγ-MG KO mice, but only specifically augmented BRCA1 in PPARγ-WTs.